Thousand of medical research reports on Cell therapy clinical benefits & over 6 million recipients by 6,000 doctors worldwide over the last 75 years.

 

 

 

These are independant Tests on MFIII

 

 

 

BIO-HC  Laboratories

Clinical Report No. TAO 01.1099

Pessac, France 2001

 

 

Lethal Doses (LD50) Toxicity Tests

Bio HC (picture of their building shown on top right) is one of Europe largest and most sophiscated Clinical Test research centre in Pessac, France under GLP (Good Laboratories Practice) and GCP (Good Clinical Practise) conditions, Bio HC in Vitro Department comprises of a group of dynamic and experienced experts. The professionals include physicians, pharmacists, dermatologists, allergologists, biochemists and bacteriologists.

 

In order to ensure MFIII of Switzerland is totally harmless and have scientific objectivity, Bio HC in Vitro Department conducted and validated toxicological and pharmacological studies on MFIII of Switzerland. The test report was further attestated and audited by PHYCHER Bio development in France.

Then MFIII of Switzerland was also further analysed by 3 other Swiss Research bodies.

 

Pharmaceutical Research

Exton, USA 2002

 

Safety Profile Assessment

 

Company Inc (PRC) USA

Pharmaceutical Research Company, Incorporated (PRC) situated in Exton, Philadelphia USA, are International Pharmaceutical Consultants to many Multi National Companies on Biotechnology, Pharmaceuticals, FDA Regulations, Analytical and Research .

 

Various samples of different batches of production of MFIII of Switzerland PE Softgels were further despatched across the continent to another independent New Zealand biotech laboratory, namely Canterbury Health Laboratories. Here, under the The Steriod and Immunology Unit headed by Professor John Lewis, PhD Steriod BioChemist, the samples were thoroughly tested on basis of dry weight and volume. Results were then redirected back to the USA for report on safety assessment under the professional guidance of American Professor Dr. Pardeep Gupta, Associate Professor, of Pharmacy at University of the Sciences, Philadelphia, USA.

 

With broard references of over 500 databases on chemical, pharmaceuticals, medicine and biotechnology from USA, Europe, Japan and NIH(National Institute of Health) and professional expertise, PRC certified and authenticated that

Marine Cell Extracts (MFIII of Switzerland PE Softgels) is SAFE for human consumption on January 28, 2003.

 

 

Sun Yat-Sun

University Hospital

Guang Chou, China 2005

 

 

Independent Clinical Research & Testing

was carried out by Sun-Yat-Sun University Hospital, one of 2 China's renowned universities for Clinical trials. The findings was published in Chinese Journal and the Dermatology magazine of one Anti-aging Association.

 

 

 

State Food & Drug

Administration, China

Beijing, China 2005/2006

 

China SFDA Safety, Toxicity & Clinical Testing Approval

One of the very pre-requisite for oral supplement approvals in China was their very stringent independent SFDA government lab testings for safety, toxicity and efficacy. MFIII went through all these vigourous testing, trials, one by one.  MFIII was clinically tested by Beijing Ke Siang Ba Ya Medical Research Technology Company and approved by China SFDA. In early 2006, the approval SFDA report no: 200606008 on all in testings was out successfully.

 

 

Switzerland 2005/2006

 

Lab. Intercosmetica

- Zepter Group

Swiss Independent Randomised Double-Blind Placebo* Controlled Study

was headed by Professor Dr. Alain Begiun, commitee of Swiss Society of Cosmetic Chemists Swiss (SCC) and a team of Swiss professional clinicians. Clinical Report No. CTE 23A. The Proven Clinical Study was published and presented in Medical Journals and Medical Dermatology Conference of Anti-aging in Paris Europe in Oct. 2006.

Clinical Studies

 

 

CLINICALY PROVEN EVIDENCED BASED SKIN REJUVENATION EFFECTS

Within 2 months the older group shows a skin rejuvenation level of about 20 years, based on the epidemis+dermis density.

 

 

 

Demography

• Venue of study: Neuchatel Switzerland
• Time: September, 2005 to January 2006
• 2 groups of volunteers: Test group, Placebo group
• Healthy women, Caucasian skin type, Various races
• Skin phototype II (Fitzpatrick)
• Ages: Group ranging from 20-60 years, mean 41
• Volunteers nor research conducting personnel are aware which is the real PE Softgels nor its name or a Placebo as softgels looks totally alike.

 

Study on human volunteers (in vivo)

• Double-blind placebo-controlled clinical study
• 58 women aged 20-60
• No study-related side-effects reported
• 11 skin bioengineering parameters studied

Study on human volunteers (in vivo) (2)

• Noticeable effects already after four weeks
• Significant reduction of microscars after 3 months
• Improved skin smoothness
• Improved skin firmness (=dermis density)
• Reduced fine lines and wrinkles

Clinically Proven evidence of a skin smoothing effect

Computerized skin profilometry  (on skin microrelief, average roughness, forearm etc)

 

CONCLUSION ON RESULTS

 

 

Selected example of skin surface smoothing (vol. #12, age 46):

 

 

BEFORE TREATMENT

1  MONTH

2  MONTH

3  MONTH

A stepwise skin surface improvement can be followed up visually:

- SMOOTHER and LESS DRY SKIN!

 

(less white areas)

 

What is Cell Therapy?  |   Benefits  |    Products  |  Quality Assurance  |   Celebrity Club |   FAQ